|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we retrospectively studied 595 Chinese CLL patients to determine the best cutoff value for IGHV in Chinese CLL population.
|
31849198 |
2020 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, using ChIP-sequencing, we identified EZH2 and H3K27me3 target genes in two prognostic subgroups of CLL with distinct prognosis and outcome, i.e., cases with unmutated (U-CLL, n = 6) or mutated IGHV genes (M-CLL, n = 6).
|
31216925 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CLL cases can be divided in two subgroups with different clinical course based on the mutational status of the immunoglobulin heavy variable (IGHV) genes: mutated CLL (M-CLL) and unmutated CLL (U-CLL).
|
31108207 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the question remains of how to treat treatment-naive patients with IGHV-unmutated chronic lymphocytic leukaemia.
|
31582354 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we demonstrate that the mithralog EC-7072 displays high <i>ex vivo</i> cytotoxic activity against leukemia cells from CLL patients independently from high-risk prognostic markers and IGHV mutational status.
|
31681329 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
The n-CLL, i-CLL, and m-CLL signatures were found in 80% (n = 245/305), 17% (53/305), and 2% (7/305) of IGHV-unmutated (IGHV-U) cases, respectively, and in 9%, (19/216), 50% (108/216), and 41% (89/216) of IGHV-M cases, respectively.
|
31434681 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The different types of drug resistance encountered in chronic lymphocytic leukemia (CLL) cannot be fully accounted for by the 17p deletion (and/or TP53 mutation), a complex karyotype (CK), immunoglobulin heavy-chain variable region genes (IGHV) status and gene mutations.
|
31066214 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutated IGHV was detected in 71·2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene.
|
31230372 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with mutated IGHV CLL more often had mutations in KLHL6 (P = 0·001) and MYD88 (P < 0·001).
|
30924136 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We herein suggest that the combined assessment of the IGHV mutational status and CK subtypes refines the prognostication of CLL, allowing to identify M-IGHV patients without any CK subtypes who are characterised by an indolent disease and excellent outcome after chemoimmunotherapy.
|
31209327 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we used a quantitative label-free proteomic technique to ascertain differences in the B-cell proteome from healthy donors and CLL patients with either mutated (M-CLL) or unmutated (UM-CLL) IGHV to identify new prognostic markers.
|
30656643 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied whether bendamustine (BENDA) alone or with rituximab (RIT) modifies <i>in vitro</i> expression of apoptosis-involved genes and proteins of chronic lymphocytic leukemia (CLL) cells depending on IGVH mutational status.
|
30187811 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, the immunoglobulin heavy chain variable region repertoire was distinct from those reported in CLL or MZL.
|
31590326 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most important markers in chronic lymphocytic leukemia (CLL) are TP53 abnormalities, including mutations and deletions, and the mutational status of immunoglobulin heavy chain (IGHV) genes.
|
31371221 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ibrutinib is active for patients with chronic lymphocytic leukaemia irrespective of IGHV mutation status but requires continuous treatment.
|
31208944 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We here describe a patient affected by CLL with a mutated IGHV status, showing a balanced t(1;3)(q23.1;q21.3) translocation and a der(18)t(1;18)(q24.2;p11.32), accompanying the recurrent 13q14 heterozygous deletion in all analyzed cells at onset.
|
30877410 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, in certain instances, as in the case of chronic lymphocytic leukemia (CLL), the clonotypic IG sequence and, more specifically, the load of somatic hypermutations within the rearranged IG heavy variable (IGHV) gene, holds prognostic and potentially predictive value.
|
30350197 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, we demonstrate that relative increase of SETA to SETB mRNA can discriminate patients with a more aggressive disease course within the otherwise favourable CLL risk classifications of IGHV mutated and favourable hierarchical fluorescence in situ hybridisation groups.
|
30443898 |
2019 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.
|
31054420 |
2019 |
|
LOC102724971
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL).
|
31447270 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The abnormal expression of miRNAs may play critical roles in the occurrence, development and prognosis of chronic lymphocytic leukemia (CLL), with potential ethnic differences being involved. p53 and immunoglobulin heavy chain variable region gene (IGVH) mutations were monitored and miRNA profile screening of CD19 <sup>+</sup> cells from Uygur CLL patients was performed, analyzed by miRNA arrays and verified using real-time PCR.
|
31425738 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.
|
31582540 |
2019 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Importantly, we confirmed by multivariate analysis that this was independent of IgHV mutational status or subset #2 stereotyped receptor (<i>P</i> < 0.0001).<b>Conclusions:</b> We have demonstrated for the first time that a light chain can affect CLL prognosis and that IgLV3-21 light chain usage defines a new subgroup of CLL patients with poor prognosis.<i></i>.
|
29945996 |
2018 |
|
LOC102724971
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both CLL and MCL include 2 major molecular subtypes that seem to derive from antigen-experienced CD5<sup>+</sup> B cells that retain a naive or memory-like epigenetic signature and carry a variable load of immunoglobulin heavy-chain variable region somatic mutations from truly unmutated to highly mutated, respectively.
|
29666114 |
2018 |
|
LOC102724971
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to EBV<sup>-</sup> tumours, EBV<sup>+</sup> DLBCLs derived predominantly from IGVH-hypermutated CLL, and they also showed CLL-unrelated IGVH sequences more frequently.
|
29464716 |
2018 |